Results 41 to 50 of about 75,066 (195)

Direct visualization of glucagon‐like peptide‐1 secretion by fluorescent fusion proteins

Journal of Diabetes Investigation, 2022
Live‐cell imaging with fluorescent proteins (FPs) is a powerful tool for investigating the exocytosis processes of hormones. However, the secretion process of glucagon‐like peptide‐1 (GLP‐1) has not been visualized by FPs, which might be because tagging ...
Atsushi Tsuzuki, Yoichiro Fujioka, Aiko Yoshida, Sayaka Kashiwagi, Maho Amano, Tohru Hira, Akinobu Nakamura, Hideaki Miyoshi, Tatsuya Atsumi, Yusuke Ohba   +9 more
doaj   +1 more source

Diabetes and the Metabolic Syndrome as Drivers of Neurodegeneration: Convergent Mechanisms Linking Peripheral Neuropathy and Dementia

Annals of Neurology, EarlyView.
The metabolic syndrome, a state of progressive metabolic dysfunction, injures the peripheral and central nervous systems, promoting peripheral neuropathy (PN) and cognitive impairment (CI), respectively. We posit PN and CI are connected in the metabolic syndrome framework, built on the premise that neurons, whether in the peripheral or central nervous ...
Masha G. Savelieff, David L. Bennett, Troels S. Jensen, Eva L. Feldman   +3 more
wiley   +1 more source

Glucagon-like peptide-1: a new potential regulator for mesenchymal stem cells in the treatment of type 2 diabetes mellitus and its complication

Stem Cell Research & Therapy
Glucagon-like peptide-1 is an enteric proinsulin hormone secreted by intestinal L-cells that orchestrates insulin secretion in a glucose-dependent manner.
Zi’an Shao, Xiaoguang Zhang, Junrong Cai, Feng Lu   +3 more
doaj   +1 more source

Super-resolution microscopy compatible fluorescent probes reveal endogenous glucagon-like peptide-1 receptor distribution and dynamics

Nature Communications, 2020
Glucagon-like peptide-1 receptor is an important regulator of appetite and glucose homeostasis. Here the authors describe super-resolution microscopy and in vivo imaging compatible fluorescent probes, which reveal endogenous glucagon-like peptide-1 ...
Julia Ast, Anastasia Arvaniti, Nicholas H. F. Fine, Daniela Nasteska, Fiona B. Ashford, Zania Stamataki, Zsombor Koszegi, Andrea Bacon, Ben J. Jones, Maria A. Lucey, Shugo Sasaki, Daniel I. Brierley, Benoit Hastoy, Alejandra Tomas, Giuseppe D’Agostino, Frank Reimann, Francis C. Lynn, Christopher A. Reissaus, Amelia K. Linnemann, Elisa D’Este, Davide Calebiro, Stefan Trapp, Kai Johnsson, Tom Podewin, Johannes Broichhagen, David J. Hodson   +25 more
doaj   +1 more source

Glucagon-like peptide-1 agonist use for obesity treatment in patients with left ventricular assist devices

JHLT Open
Glucagon-like peptide-1 agonists are effective weight loss treatments, yet few data are available regarding their use in patients with durable left ventricular assist devices.
Michele Edwards, MSN, APRN, Melanie Thomas, MSN, APRN, Maryjane Farr, MD, MSc, Densey Varghese, MSN, APRN, Lauren K. Truby, MD, MS, Jennifer T. Thibodeau, MD, MSCS, Mark H. Drazner, MD, MSc, Matthias Peltz, MD, Justin L. Grodin, MD, MPH, Nicholas S. Hendren, MD   +9 more
doaj   +1 more source

The deletion of glucagon-like peptide-1 receptors expressing neurons in the dorsomedial hypothalamic nucleus disrupts the diurnal feeding pattern and induces hyperphagia and obesity

Nutrition & Metabolism, 2021
Background Feeding rhythm disruption contributes to the development of obesity. The receptors of glucagon-like peptide-1 (GLP-1) are distributed in the wide regions of the brain.
Yuko Maejima, Shoko Yokota, Masaru Shimizu, Shoichiro Horita, Daisuke Kobayashi, Akihiro Hazama, Kenju Shimomura   +6 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist Use in Obese Patients Is Associated With Decreased Risk of Revision and Retears After Arthroscopic Rotator Cuff Repair

Arthroscopy, EarlyView.
Purpose To evaluate the impact of preoperative glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use on medical complications, emergency department use, and orthopaedic complications in obese patients undergoing arthroscopic rotator cuff repair. Methods Obese patients (defined by relevant ICD‐10 codes and confirmed by body mass index measurements ...
Argen Omurzakov, Arsen M. Omurzakov, Robert J. Burkhart, James E. Voos, Jacob G. Calcei, John M. Apostolakos   +5 more
wiley   +1 more source

Commentary on “Electroacupuncture Inhibited Spinal Glial Activation in Neuropathic Pain via Glucagon-like Peptide 1/Glucagon-like Peptide 1 Receptor Signaling”

Neurological Sciences and Neurophysiology
Neuropathic pain represents a significant clinical challenge due to its complex etiology and limited treatment options. Traditional pharmacological approaches, particularly opioid therapy, are associated with significant side effects and risk of abuse ...
Hulya Karatas
doaj   +1 more source

Enteroendocrine L Cells Sense LPS after Gut Barrier Injury to Enhance GLP-1 Secretion

Cell Reports, 2017
Summary: Glucagon-like peptide 1 (GLP-1) is a hormone released from enteroendocrine L cells. Although first described as a glucoregulatory incretin hormone, GLP-1 also suppresses inflammation and promotes mucosal integrity.
Lorène J. Lebrun, Kaatje Lenaerts, Dorien Kiers, Jean-Paul Pais de Barros, Naig Le Guern, Jiri Plesnik, Charles Thomas, Thibaut Bourgeois, Cornelis H.C. Dejong, Matthijs Kox, Inca H.R. Hundscheid, Naim Akhtar Khan, Stéphane Mandard, Valérie Deckert, Peter Pickkers, Daniel J. Drucker, Laurent Lagrost, Jacques Grober   +17 more
doaj   +1 more source

Gut Health in Ostriches (Struthio camelus): Insights Into Intestinal Structure, Functions, Microbiome, and Improvement Strategies

Animal Research and One Health, EarlyView.
Our paper systematically reviews the intestinal structure, function, and microbiota of ostriches, along with strategies for improving their gut health. We analyze how these factors collectively influence intestinal homeostasis and ostrich welfare, emphasizing probiotics as a promising intervention to enhance gut health, boost population well‐being, and
Zi‐Qun Zhang, Fang‐Fang Guo, Wen‐Juan Du, Meng Li, Aftab Shaukat, Zhu‐Qing Jia, Shu‐Cheng Huang   +6 more
wiley   +1 more source